Freespira

Executive Summary

Freespira is a digital health company offering an FDA-cleared, clinically proven breathing-based treatment for anxiety and panic disorders. Founded in 2012 and headquartered in Kirkland, Washington, the company has developed a home-use device and coaching program that normalizes respiratory patterns to alleviate symptoms. Its technology is supported by multiple clinical studies and has secured FDA clearance as a treatment option, distinguishing it in the growing digital therapeutics market for mental health. With anxiety and panic disorders affecting millions worldwide, Freespira addresses a significant unmet need for non-pharmacological, accessible interventions. The company operates in the digital health and neuroscience sectors, positioning itself at the intersection of behavioral health and medical device innovation. Though Freespira is a private company with limited public financial disclosures, its validated clinical outcomes and FDA clearance provide a strong foundation for commercialization and potential partnerships. The company could benefit from increasing insurer reimbursement for digital therapeutics and growing awareness of breathing-based interventions. However, it faces competition from other digital therapeutics platforms and traditional treatments. Key catalysts include expansion into new indications (e.g., PTSD or depression), strategic partnerships with healthcare systems or payers, and further clinical evidence supporting long-term efficacy. These developments could accelerate adoption and drive valuation growth.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance expansion to additional anxiety-related indications (e.g., PTSD)60% success
• Q3 2026Announcement of major payer coverage or partnership with a national health system50% success
• Q3 2026Publication of new clinical trial data demonstrating long-term efficacy or superiority over standard care70% success